Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

NexMed completes phase I trial of ED product

Feb. 4, 1998

Androtab-SL NDA is inadequate for approval, FDA says

Feb. 3, 1998

EPO peptides and anti-EPO antibodies from Behringwerke

Feb. 3, 1998

Somatostatin receptor ligands synthesized by Novo Nordisk

Feb. 2, 1998

Schering-Plough to copromote Novo Nordisk's Prandin

Jan. 30, 1998

Oxytocin antagonist licensed by Tokyo Tanabe enters clinic

Jan. 30, 1998

Roche patents vitamin D analogues for osteoporosis

Jan. 30, 1998

Comparative trial of intracavernous alprostadil and MUSE for ED

Jan. 29, 1998

BioMarin's lead enzyme replacement therapy enters clinical trials

Jan. 28, 1998

Common variant of CETP gene correlated with atherosclerosis progression, response to pravastatin

Jan. 27, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...